RESEARCH

Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium

Jyotirmayee Dey1†, Soumya Ranjan Mahapatra1†, T. Kiran Raj2, Taranjeet Kaur3, Parul Jain1, Arushi Tiwari1, Shubhransu Patro4, Namrata Misra1,5* and Mrutyunjay Suar1,5*

Abstract

Enterococcus faecium is an emerging ESKAPE bacterium that is capable of causing severe public health complications in humans. There are currently no licensed treatments or vaccinations to combat the deadly pathogen. We aimed to design a potent and novel prophylactic chimeric vaccine against E. faecium through an immunoinformatics approach. The antigenic Penicillin-binding protein 5 (PBP 5) protein was selected to identify B and T cell epitopes, followed by conservancy analysis, population coverage, physiochemical assessment, secondary and tertiary structural analysis. Using various immunoinformatics methods and tools, two linear B-cell epitopes, five CTL epitopes, and two HTL epitopes were finally selected for vaccine development. The constructed vaccine was determined to be highly immunogenic, cytokine-producing, antigenic, non-toxic, non-allergenic, and stable, as well as potentially effective against E. faecium. In addition, disulfide engineering, codon adaptation, and in silico cloning, were used to improve stability and expression efficiency in the host E. coli. Molecular docking and molecular dynamics simulations indicated that the structure of the vaccine is stable and has a high affinity for the TLR4 receptor. The immune simulation results revealed that both B and T cells had an increased response to the vaccination component. Conclusively, the in-depth in silico analysis suggests, the proposed vaccine to elicit a robust immune response against E. faecium infection and hence a promising target for further experimental trials.

Keywords: Enterococcus faecium, Penicillin-binding protein, Vaccine, Epitope, Immunoinformatics

Introduction

Enterococcus faecium is among the most frequent causes of healthcare-associated infections with underlying co-morbidities such as UTIs, intra-abdominal infection, prostatitis, organ transplantation, diabetes, endocarditis [1]. E. faecium is also reported as the second most prevalent organism involved in bloodstream infections and rank fourth in terms of surgical site infections in the US and European hospitals [2, 3]. Cassini et al. reported 16,146 instances of vancomycin-resistant enterococcal infections and 1081 related fatalities in Europe in 2015 [4]. According to Ferede et al. the prevalence rate of E. faecium in India was found to be 2.3% [5]. On average, 2.5 million people become infected with antibiotic-resistant E. faecium, and more than 25,000 people die each year across the world. The annual incidence of E. faecium is...
leads to poor outcomes, and it remains a challenge. Infection caused by VRE comycin-resistant enterococci (VRE) has increased in these infections. In the last decade, the number of van- tide vancomycin was the antibiotic employed to treat treatment of infections caused due to E. faecium beta-lactams are the major antibiotics available for the cephalosporins, trimethoprim/sulfamethoxazole, and comycin macrolides, oxazolidinones, clindamycin, clindamycin, Penicillin-binding protein 5 (PBP 5) (accession id: protein sequence Retrieval of protein sequence in Fig. 1. Methodology The pictorial representation of the workflow is depicted in Fig. 1. Retrieval of protein sequence The amino acid sequence of the major secreted protein, Penicillin-binding protein 5 (PBP 5) (accession id:
G5CKR9) of Enterococcus faecium was obtained from the UniProt database (https://www.uniprot.org/). The accession Id of the protein was derived from the manual search in the search bar of the UniProt database.

**Linear B lymphocyte (LBL) epitope prediction**
The ABCpred server (http://crdd.osdd.net/ragava/abcpred/ABC_submission.html) was used to predict linear B cell epitopes. FASTA sequence with a window length of 10 was given as input and the program provided 10mer epitopes with a default specificity of 75% for B-cell receptors. The epitope with the best score was chosen for the future development of a multi-epitope vaccine [18].

**Cytotoxic T lymphocyte (CTL) epitope prediction**
Prediction of CTL epitopes of the target protein was rendered using NetMHCpan4.1 (http://www.cbs.dtu.dk/services/NetMHCpan-4.1/) server. The threshold for epitope identification for a strong binder was set at 0.5% while at 2% for a weak binder. The server predicts epitopes for 12 HLA class I supertypes. The epitopes from each supertype were predicted. ‘Sort by Prediction score’ was selected. Prior to prediction, all the epitope lengths were set as 9mers, conserved epitopes that bind to many HLA alleles [19].

**Helper T lymphocyte (HTL) epitope prediction**
For predicting (15mer) HTL, the selected protein was given as input in the IEDB (Immune Epitope Database) MHC II binding tool. The HTL epitopes were predicted using the whole HLA (Human leukocyte antigen) reference set. It covers all HLA class II alleles including HLA-DR, HLA-DQ, and HLA-DP. The suggested IEDB parameters were utilized to make the prediction, which included a complete set of 27 human alleles that covered 99% of the population. The window length was kept at 15 and the peptides were sorted according to the adjusted rank. HTL epitopes were chosen based on their IC50 (Inhibition concentration 50) values, the epitopes with low IC50 values (IC50 value represents the minimal concentration of a drug that is required for 50% inhibition in vitro) displaying strong affinity [20].

**Antigenicity, allergenicity, and toxicity assessment**
The antigenicity was predicted using the Vaxijen v2.0 server (http://www.ddg-pharmfac.net/vaxijen/Vaxijen/Vaxijen.html). This software requires epitope sequence to certify antigen classification uniquely based on the physicochemical properties. In contrast to bacterial species, the default settings (threshold=0.4, ACC output) were utilized to predict the antigenicity of the epitopes sequence [21].

![Fig. 1](image-url) The schematic representation of the immunoinformatics guided design of the multi-epitope vaccine construct against Enterococcus faecium
AllerTOP v. 2.0 (https://www.ddg-pharmfac.net/AllerTOP/feedback.py), a bioinformatics tool for allergenicity prediction, was used to estimate if epitopes extracted from bacterial protein sequences would cause an allergic reaction in humans. To calculate the allergenicity of the sequence, all of the epitopes in the plain text were used as input [22].

ToxinPred (https://webs.iiitd.edu.in/raghava/toxinpred/multi/submit.php) was used to forecast the toxicity of specified epitopes. All peptides were entered in FASTA format, and all other settings were left at their default values [23].

Another tool from the IEDB Analysis Resource, Class I Immunogenicity (http://tools.iedb.org/immunogenicity/), was used to estimate the degree of immunogenicity of the chosen peptides. The epitopes were provided as input, with the rest of the settings set to default [24].

**Population coverage analysis**

The population of anticipated epitopes was determined using the IEDB population coverage tool (http://tools.iedb.org/population/). To perform predictions, the epitopes and alleles were given as inputs. The IEDB recommended method is the default setting and usually is consensus, a combination of three different methods (ANN, SMM, and Combinatorial Library). For humans, the most frequent alleles are available for selection by default [25].

**Construction of multi‑epitope vaccine**

Because of their small size, epitopes are often non-immunogenic when used alone as a vaccine [26]. To activate the innate and adaptive immune systems, they need a carrier with potent immuno-stimulatory adjuvants. Linkers play a critical role in replicating the vaccine construct’s ability to serve as an independent immunogen and produce higher antibody concentrations than a single immunogen [27]. To boost the stability and antigenicity of the final vaccine, selected LBL, CTL, and HTL epitopes were connected with linkers such as KK, AAY, and GPGPG, respectively. LBL epitopes were joined with ‘KK’ linkers, CTL epitopes were joined with ‘AAY’ linkers, and HTL epitopes were joined with ‘GPGPG’ linkers. Adjuvant was attached with the help of EAAAK linker to the N terminal end of the vaccine.

**Physiochemical properties of the constructed vaccine**

The ProtParam server (https://web.expasy.org/protparam/) was used to determine the physical and chemical characteristics of the final vaccine, including amino acid composition, theoretical pl, instability index, in-vitro and in-vivo half-life, aliphatic index, molecular weight, and grand average of hydropathicity (GRAVY).

**Secondary structure prediction**

PSIPRED (http://bioinf.cs.ucl.ac.uk/) was used to estimate the secondary structure of the vaccine’s main amino acid sequence. ‘PSIPRED 4.0 (Predict secondary structure)’ option was chosen from the ‘popular analyses’ section [28]. The complete sequence was analyzed by default.

**Predicting tertiary structure and validation**

The predicted subunit vaccine candidate’s 3D structure was retrieved using the Robetta internet server (https://robeta.bakerlab.org/). For structure prediction, the target name and vaccine sequence was submitted to the server. The tertiary structure was provided through the web interface. The visualization of the structure was done using the pymol visualization software. After that, the validation of the protein structure was performed through PROCHECK (https://services.mbi.ucla.edu/SAVES/), ERRAT (https://services.mbi.ucla.edu/SAVES/), and Verify 3D (https://services.mbi.ucla.edu/SAVES/) online servers. The structure was submitted to these servers in PDB (Protein Data Bank) format.

**Disulphide engineering of the final vaccine construct**

To boost stability, the vaccine structure was submitted to the Disulphide by Design (DbD) 2.12 tool (http://cpt-web.cpt.wayne.edu/DbD2/). Potential residue pairings were chosen based on a set of parameters (87 to +97 chi3 value and <2.2 energy value) and mutated with a cysteine residue [29].

**Discontinuous B‑cell epitope prediction**

To anticipate the discontinuous B-cell epitopes in the final vaccine structure, the ElliPro server (http://tools.iedb.org/ellipro/) was employed [30]. The PDB structure was given as input. The threshold values were set at default. The minimum residue score (protrusion index) was between 0.5 and 1.0 and the maximum distance was in the range 4–8 Å. It assigns an ellipsoid score to each residue, which is characterized as a PI (Protrusion Index) value based on the 3D structure of the vaccine.

**Molecular docking**

The tertiary structure of the muti-epitope vaccine was examined as a ligand molecule, and TLR-4 (PDB ID: 5IJB) was chosen as the receptor. Docking was performed by the Autodock 4.0 program using the empirical free energy function and the Lamarckian Genetic algorithm [31]. Partial charges were added to the ligand, and the non-polar hydrogens were linked. The grid map was created with Autogrid, with a grid box diameter of 90*90*90
and a spacing of 0.35 angstrom. Based on the reactive distances and binding energies, the optimum conformation of the interaction was determined after docking.

Molecular dynamics simulation
Molecular dynamics simulations were performed using the GROMACS-2019.4 version [32, 33] using the Gromos force field and SPC-2 water model. Energy minimization was used to remove high energy configurations (bonded terms distant from equilibrium or steric conflicts). The system then proceeds to equilibrate the atoms of molecules with NVT for 500 ps at a temperature of 300 K. Similarly, the NPT equilibrium operates at 1 bar pressure and 300 K. Following the equilibration procedure, a 100 ns MD simulation of the receptor (TLR-4) and ligand (final vaccine design) complex was performed. The trajectory file obtained by the MD simulation was examined using the GROMACS commands gmx rms, gmx rmsf, gmx gyrate, and gmx hbond to obtain the root-mean-square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration, and hydrogen bond interaction, respectively.

Codon adaptation and in silico cloning of the vaccine
The greater expression rates might be due to a distinct codon adaptation technique that was adapted to E. coli K12, the most sequenced prokaryotic organism. In the instance of the host organism E. coli K12, the approach was utilized to increase the expression of the main sequence of the subunit vaccination protein, which was subsequently sent to the JAVA Codon Adaptation Tool. Prokaryote ribosome binding site, rho independent transcription termination, and restriction enzyme cleavage site were all avoided. Using the restriction cloning module of the SnapGene program, the altered nucleotide sequences of the developed multi-subunit vaccine were further cloned into the E. coli pET-28a (+) vector between restriction sites (GSL Biotech, available at snapgene.com).

Immune simulation
Immune simulations were run on the ClImmSim server (http://150.146.2.1/C-IMMSIM/index.php) to verify the expected MEV’s immune response. The MEV’s capacity to activate immune system cells such as NK cells, HTL, B-cells, CTL, immunoglobulins, cytokines, and dendritic cells was investigated. A four-week interval between two vaccination doses is advised in clinical practice. Immune simulation was done using a technique that was similar to this system. In a nutshell, every 4 weeks, three shots were given. The total number of simulation steps was 1050.

Results
Criteria for epitope prediction
Toxic and allergic epitopes should be avoided since they can endanger the goal of vaccine development. Antigenicity, allergenicity, toxicity, and immunogenicity of anticipated epitopes were assessed using Vaxigen v2.0, AllerTOP v2.0, Toxinpred, and the IEDB class I immunogenicity tool, respectively. For further investigation, epitopes with positive immunogenicity scores, high antigenicity, non-allergenicity, and nontoxic nature were chosen.

Prediction of linear B-cell epitopes
The ABCpred server was used to examine the protein's amino acid sequences for the presence of linear epitopes. A total of 30 epitopes of length 10 mer were predicted as mentioned in Additional file 1: Table S1. Only two epitopes (DADGVEKKVL and DIKLITIDAKA) were chosen for the final vaccine construct based on the above-mentioned criteria (Table 1).

Prediction of cytotoxic T lymphocytes epitope
MHC Class I binding peptides were predicted using the NetMHCPan 4.1 server (Additional file 2: Table S2). The top five peptides from having high antigenicity and positive immunogenicity score were shortlisted for the final vaccine construct and are shown in Table 2.

Prediction of helper T lymphocytes epitope
Peptides that bind to MHC class II molecules were predicted using the IEDB server’s MHC class II binding peptide prediction tool. The IEDB-recommended approach was employed for MHC class II binding, and a reference set of 27 alleles was used. As shown in Additional file 3: Table S3, a total of 10 HTL epitopes and their matching HLA class II binding alleles were predicted for the protein sequence. Based on the above criteria, the top two HTL epitopes (DKFIIFGEDLDLPIASM and DSLGGKAGSTVATT) were selected for the final vaccine construction (Table 3).

Population coverage analysis of the selected epitopes
Individual and combinatory population coverage for the seven chosen T-cell epitopes (5 CTL and 2 HTL) with their binding HLA alleles was calculated, as shown in Additional file 4: Table S4. Global population coverage of 99.25% and 96.20% individuals will respond to the selected epitopes in India. West Africa had the highest population coverage of 99.93%.

Construction of the multiteptide vaccine candidate
Finally, a 172 amino acid long multi-peptide vaccine was created by connecting several epitopes such as LBL, CTL,
### Table 1
Final selected B-cell epitopes from *Enterococcus faecium* penicillin binding protein and their corresponding immunogenic properties

| Uniprot_ID | B-cell epitope | Position | Score | Antigenicity score | Toxicity   | Hydrophobicity | Hydropathicity | Hydrophilicity | Charge | Mol wt   |
|------------|----------------|----------|-------|--------------------|------------|----------------|----------------|----------------|--------|----------|
| G5CK9      | DADGVEKKVL     | 323      | 0.77  | 1.905              | Non-toxin  | −0.22          | −0.47          | 0.97           | −1     | 1073.35  |
| DIKLTDXA   |                | 342      | 0.71  | 1.8105             | Non-toxin  | −0.13          | 0.09           | 0.52           | 0      | 1087.42  |
Table 2  Predicted CTL epitopes from *Enterococcus faecium* penicillin binding protein to design multi-epitope vaccine construct with their corresponding MHC Class I alleles and their immunogenic properties

| Uniprot_ID | CTL epitope | Alleles | Position | Score | Antigenicity score | Immunogenicity | Toxicity | Hydrophobicity | Hydropathicity | Hydrophilicity | Charge | Mol wt |
|-----------|-------------|---------|----------|-------|--------------------|----------------|----------|----------------|----------------|---------------|--------|--------|
| G5CKR9    | KLGDGGKT    | HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-A*26:01, HLA-B*07:02, HLA-B*08:01, HLA-B*27:05, HLA-B*39:01, HLA-B*40:01, HLA-B*58:01, HLA-B*15:01 | 199  | 3.466 | 2.5192 | 0.05672 | Non-toxin | −0.3 | −1.43 | 1.09 | 0 | 904.12 |
| KJADKETK  | HLA-A*03:01, HLA-A*26:01, HLA-B*07:02, HLA-B*08:01, HLA-B*27:05, HLA-B*39:01, HLA-B*40:01, HLA-A*01:01, HLA-A*02:01, HLA-A*24:02, HLA-B*58:01, HLA-B*15:01 | 567  | 0.395 | 0.4315 | 0.00835 | Non-toxin | −0.37 | −1.03 | 1.17 | 1 | 1045.37 |
| TTNWQPNL  | HLA-A*24:02, HLA-B*07:02, HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*26:01, HLA-B*08:01, HLA-B*27:05, HLA-B*39:01, HLA-B*40:01, HLA-B*58:01, HLA-B*15:01 | 145  | 3.248 | 1.4839 | 0.13021 | Non-toxin | −0.09 | −0.68 | −0.8 | 0 | 1086.35 |
| EVDGYYPL  | HLA-B*58:01, HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-A*26:01, HLA-B*07:02, HLA-B*08:01, HLA-B*27:05, HLA-B*39:01, HLA-B*40:01, HLA-B*58:01, HLA-B*15:01 | 259  | 0.794 | 1.6871 | 0.07862 | Non-toxin | −0.21 | −0.9 | 0.12 | −1 | 1111.34 |
| LRGTGGKL  | HLA-B*27:05, HLA-A*24:02, HLA-A*26:01, HLA-B*07:02, HLA-B*58:01, HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-B*08:01, HLA-B*39:01, HLA-B*40:01, HLA-B*15:01 | 311  | 2.321 | 1.9864 | 2.321 | Non-toxin | −0.19 | −0.38 | 0.18 | 2 | 902.2 |

Dey et al. Gut Pathogens           (2022) 14:21
Table 3 Predicted HTL epitopes from *Enterococcus faecium* penicillin binding protein to design multi-epitope vaccine construct with their corresponding MHC Class II alleles and their immunogenic properties

| Uniprot_ID | MHC II epitope | Alleles | Pos | ICS0 value | Percentile_Rank | Antigencity Score | Toxicity | Hydrophobicity | Hydropathicity | Hydrophilicity | Charge | Mol wt |
|------------|----------------|---------|-----|------------|-----------------|-------------------|----------|----------------|----------------|---------------|--------|--------|
| G5CKK9     | DKFIFGEDLDLPISM | HLA-DRB1*01:01, HLA-DPA1*01:01, HLA-DPB1*02:01, HLA-DPB1*01:01, HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*13:02, HLA-DRB1*11:01, HLA-DRB1*04:01, HLA-DRB1*12:01, HLA-DPA1*03:01, HLA-DPB1*04:02, HLA-DRB1*04:05, HLA-DRB1*15:01, HLA-DQA1*01:01, HLA-DQB1*05:01, HLA-DRB1*08:02, HLA-DPA1*02:01, HLA-DRB1*14:01, HLA-DRB1*04:01, HLA-DQA1*05:01, HLA-DQB1*03:01, HLA-DQA1*04:01, HLA-DQB1*04:02, HLA-DPA1*02:01, HLA-DRB1*02:01, HLA-DPA1*02:01, HLA-DRB1*05:01, HLA-DPA1*01:01, HLA-DQA1*05:01 | 502–516 | 19 | 0.87 | 0.8406 | Non-toxin | 0 | 0.23 | 0.12 | –3 | 1740.22 |
Table 3 (continued)

| Uniprot ID | MHC II epitope | Alleles | Pos | IC50 value | Percentile Rank | Antigencity Score | Toxicity | Hydrophobicity | Hydropathicity | Hydrophilicity | Charge | Mol wt |
|------------|----------------|---------|-----|------------|----------------|-------------------|----------|----------------|----------------|----------------|--------|--------|
| DSLGGKAGST-VATTP | HLA-DRB5*01:01, HLA-DRB1*15:01, HLA-DRB3*01:01, HLA-DPA1*03:01, HLA-DPB1*04:02, HLA-DPA1*01:03, HLA-DPB1*02:01, HLA-DRB1*01:01, HLA-DRB1*09:01, HLA-DRB3*02:02, HLA-DRB1*13:02, HLA-DRB1*11:01, HLA-DRB1*04:01, HLA-DRB1*12:01, HLA-DRB1*04:05, HLA-DQA1*01:01, HLA-DQ81*05:01, HLA-DRB1*08:02, HLA-DPA1*02:01, HLA-DPB1*14:01, HLA-DPA1*01:03, HLA-DPB1*04:01, HLA-DQA1*05:01, HLA-DQB1*03:01, HLA-DQA1*03:01, HLA-DQB1*03:02, HLA-DQA1*01:02, HLA-DQB1*06:02, HLA-DRB1*07:01, HLA-DRB4*01:01, HLA-DRB1*03:01 | 357–371 | 12 | 1.3 | 1.9712 | Non-toxin | −0.06 | −0.15 | 0.07 | 0 | 1361.68 |
HTL with suitable linkers at appropriate places. The final subunit vaccine was constructed using three linkers: KK, AAY, and GPGPG. The AAY and GPGPG linkers were introduced to the intra-epitope site to connect the CTL and HTL epitopes, respectively. Then, to boost the effectiveness of the immune response, human beta-defensins (accession id: P81534) of 67 amino acid length was added to the N-terminal end of the designed vaccine sequence as a molecular adjuvant. Figure 2 depicts the arrangement of adjuvant and epitopes with their connecting linkers.

Physicochemical features, solubility, and secondary structure prediction

The aliphatic index, GRAVY, Theoretical PI, instability index, and molecular mass of the multi-epitope vaccine were calculated to be 73.90, –0.472, 9.38, 18.85, and 18,294.07 Da, respectively, based on the ProtParam server data. The assessment of the protein’s molecular weight was the most important aspect throughout this phase [34, 35]. Proteins with a molecular weight of < 110 kDa are thought to be more suitable since they can be easily isolated and effectively put to vaccine development [36, 37]. Based on the study of physicochemical qualities, the vaccine design was anticipated to be stable, basic, hydrophilic, thermostable, and highly soluble following over-expression in E. coli. Furthermore, the vaccine's half-life was determined to be 30 h in human reticulocytes (in vitro), over 20 h in yeast (in vivo), and over 10 h in E. coli (in vivo). Additional file 5: Table S5 summarises the physicochemical parameter analysis results.

According to the results of the PSIPRED server, random coils are formed by 99 amino acids, α-helix by 26 amino acids, and β-strands are formed only by 47 amino acids. The overall secondary structure prediction of the developed vaccine results concluded that 57.55% are random coils, 15.11% form α-helix and 27.32% are β-strands as represented in Fig. 3.

---

**Fig. 2** The structural arrangement of B and T-cell epitopes along with linkers and adjuvant for the final multi-epitope vaccine construct.
Tertiary structure prediction and validation of the vaccine construct

The Robetta server was used to predict five tertiary structures for the vaccine construction, which were then analyzed using a Ramachandran plot to choose the optimum model. Model 3 was chosen because it provided the best arrangement of residues in allowed regions (Fig. 4). The Ramachandran plot showed that most of the residues were found in the favored (81.4%), allowed (12.9%) regions, and 2.1% in generously allowed regions, while 3.6% residue was present in the disallowed region. The model's ERRAT quality factor and Verify-3D score were 92.661 and 95.93, respectively indicate that this structure is energetically stable.
The Ramachandran plot, ERRAT, and verify3D of the multi-epitope peptide structure are shown in Fig. 5.

**Disulfide engineering for vaccine protein stability**

After running the vaccine sequence through the Disulfide by Design 2.13 tool, a total of 13 possible residue pairings that potentially form a disulfide bond were found, as shown in Additional file 6: Table S6. Taking the bond energy and \( \chi^3 \) parameters into consideration, only one pair of residues was chosen because their scores fit conventional standards, i.e. the bond energy should be less than 2.2 kcal/mol and the \( \chi^3 \) angle should be between \(-87^\circ\) and \(+97^\circ\). As illustrated in Fig. 6, a mutation pair was created on the residue pair CYS11–CYS18, which had bond energy of 1.14 kcal/mol and a \( \chi^3 \) angle of \(+96.08^\circ\).

**Mapping of discontinuous B-cell epitopes in the vaccine protein**

B lymphocytes boost humoral immunity by secreting antibodies and cytokines that neutralize foreign antigens [38, 39]. That’s why it is essential to have a sufficient number of B-cell epitopes inside the protein domain. The existence of conformational B-cell epitopes was analyzed using the ElliPro tool of the IEBD server, which found 4 conformational B-cell epitopes of 14–39 residues (Additional file 7: Table S7) with scores ranging from 0.596–0.809, as shown in Fig. 7.
Molecular docking of vaccine with TLR4 receptor

To assess the binding affinity between the vaccine construct and TLR4, docking analysis of vaccine protein with TLR4 was undertaken. Molecular docking was performed by using the grid box set in the active site region. The lowest binding energy was −856.8, and the center energy between the ligand and receptor was −671.1.

Pymol was used to visualize the interactions between the TLR4 receptor and the vaccine candidate, and the docked complex is shown in Fig. 8. Residues of the vaccine construct and TLR4 receptor were found to make polar contacts are LYS43-ASN4, ASP41-ASN4, GLU88-ARG17, GLU88-LYS8, ARG86-LYS8, SER85-LYS131, ASP83-LYS131, GLU86-GLY126, and GLU86-ARG125.

Fig. 7 The conformational B-lymphocyte epitopes present in the vaccine. The yellow spheres showing epitopes containing (A) 20 residues (AA 153–172) with 0.809, (B) 14 residues (AA 69, AA 71, and AA 88–99) with 0.745, (C) 39 residues (AA 11, AA 13–16, AA 24–40, AA 42, and AA 44–59) with 0.621, (D) 27 residues (AA 1–2, and AA 127–151) with 0.596.
GLU134-GLY130, ARG233-GLY130, ARG233-GLY130, ARG233-PRO136, GLU265-LYS62, TYR183-lys61, TYR183-ARG12, ASN159-ARG12, TYR185-LEU60, GLN187-lys57, and ASP215-lys57 with the distance of 1.7 Å, 1.9 Å, 1.8 Å, 2.4 Å, 1.8 Å, 1.7 Å, 1.8 Å, 2.3 Å, 1.7 Å, 1.8 Å, 1.7 Å, 2.2 Å, 1.8 Å, 1.7 Å, 1.6 Å, 1.9 Å, 1.7 Å and 1.8 Å, respectively.

Molecular dynamic (MD) simulation
MD simulation in an aqueous environment was used to assess the stability of the protein–protein complex. The simulation time was displayed against the produced vaccine-TLR4 complex. According to the results, the cubic box was successfully created under intermittent boundary circumstances, and neutralization and energy reduction were carried out efficiently. Here we have run a simulation for 100nsffa. The produced vaccine's RMSD plot (as a ligand) indicated values in the 0.1–0.2 nm range. Result of the root mean square deviation has been shown in Fig. 9. It is noteworthy that the system was equilibrated in a shorter period. The RMSF plot shows that the complex is overlapped except at the N and C terminal of the protein as the substrate is interacting in this region (Fig. 9). The Substrate interacting region of the system is more fluctuating.

The hydrogen bond is vital in preserving protein secondary structure, therefore an accurate description of hydrogen bond interaction is critical in protein folding simulation. Hydrogen bonding is an important nonbonded interaction in system simulation, which is dominated by electrostatic interaction. The number of hydrogen bonds is calculated using a sigmoidal function of the donor–acceptor distance as a function of hydrogen bond strength. The peak in Fig. 9 is quite high, demonstrating that integrating the polarisation effect strengthens hydrogen bonding. Furthermore, any modification in protein motif and shape can be evaluated by Gyration Radius (Fig. 9). The spherical state information about total protein volume distribution is obtained by this parameter. The results suggest that the Gyration Radius of the complex is more downwards that is a clue of constructed secondary structures and it seems that this is a result of the limitation of the main chain movement of the system.

Codon adaptation and in silico cloning
Since differences in codon use result in limited translation of foreign genes, codon adaptation is the greatest strategy to improve translational efficiency. The jCat tool was utilized to improve our developed vaccine's codon use in relation to the E. coli K12 strain. The optimized sequence had a GC content of 51.93%, indicating effective expression in the E. coli host with a Codon adaptation index (CAI) of 1. The results showed that following adaptation, the prokaryotic ribosome binding site, restriction enzyme cleavable sites and rho independent transcription terminators were all eliminated. Following that, the vaccine construct's modified codon sequence was introduced into the E. coli expression vector PET28a (+) between the EcoRI and BamHI restriction sites, as shown in Fig. 10. A 6-histidine tag was also inserted to facilitate immune-chromatographic purification of the recombinant vaccine. As a result, the clone's length was 5889 bp.

In silico immune response simulation
The C-ImmSim results show that the main immune response following vaccine administration is considerably promoted by the steady increase in immunoglobulin levels (i.e., IgM, IgG1, IgG2, IgG1 + IgG2, and IgG + IgM)
during the secondary and tertiary immunological responses (Fig. 11A). During the secondary and tertiary immune responses, the antigen level fell as well. Furthermore, the raised and maintained concentrations of the B-cell population (total, active, and plasma B-cell) and T-cell (helper T-cell, cytotoxic T-cell, regulatory T-cell) (Fig. 11B–F) clearly indicated the efficacy of the designed vaccine. After each dose, the concentration of Th1 was shown to rise. Furthermore, a higher density of dendritic and macrophage cells suggests that antigen-presenting cells efficiently process and deliver antigen to CD4+ and CD8+ cells (Fig. 11G-H). It is also obvious that the levels of several cytokines rose following exposure (Fig. 11).

Discussion
Vaccination is a widely employed technique for improving the host immune mechanism against a specific pathogen [40, 41]. Producing a range of vaccines, such as live or attenuated vaccines, is expensive, time-consuming, and takes a long time to reach the market [42, 43]. Moreover, the attenuated vaccine delivers poor passive immunization and causes allergic responses due to the large antigenic load [44]. With the advancement of multi-omics technology, it is now easier for identification of epitopes that elicit strong immune response. Multi-epitopes-driven vaccines against *N. meningitidis* and *M. leprae* have been developed utilizing immunoinformatics methodologies [45, 46].

*Enterococcus faecium* is a life-threatening bacterium that has recently arisen at an alarming pace. Limited advances have been made in the elucidation of the host immune response against invasive *E. faecium* infections. The innate immune defense system depends on the recognition of the pathogen-associated molecular patterns (PAMPs). PAMPs are recognized through pattern recognition receptors, e.g., the components of the complement system and the Toll-like receptors (TLRs). There is evidence that TLR 2 (Toll-like receptor 2) plays a significant role in the innate immune response against *E. faecium* by recognizing peptidoglycan and lipoteichoic acid. Apart from this direct interaction of the pathogen with the phagocyte, there is also an indirect pathway mediated through opsonins, comprised of immunoglobulins and complement components. Activation of the alternative complement pathway elicits deposition of the complement component on the bacterial surface, which
is subsequently recognized by complement receptors on the phagocytes [47]. The incompetence of the immune system to kill the intracellular enterococci may lead to their systemic spread.

As a result, developing possible vaccinations might be a boon in the battle against this bacteria. A possible vaccine has been designed as an optimal option to prevent E. faecium infection in the current investigation. Penicillin-binding protein, a protein associated with the bacteria’s pathogenicity, was chosen based on its antigenicity score, since the higher the antigenicity, the greater the immune response. Various databases were used to anticipate potential T and B-cell epitopes, and their viability for use as a vaccine candidate was investigated. CTL epitopes help in the recognition of foreign antigen fragments on MHC-I (major histocompatibility complex-I) molecules and destroy target cells whereas HTL epitopes are required for both humoral and cell-mediated immune responses. B-cell epitopes are also significant in the development of epitopic vaccines as well as disease detection. As a result, prediction of these epitopes are critical for the creation of an immunotherapeutic and preventive vaccination. Antigenicity prediction of the protein sequence is important because it indicates whether the bacterial protein sequence is likely to be recognized by immunogenic cells in the human body. ABCpred, NetMHCpan 4.1, and IEDB MHC II prediction tools was used to predict putative B-cell, CTL, and HTL epitopes. All of the epitopes were found to be ‘antigenic’ as analyzed by the VaxigenV2.0 server. Another prominent obstacle in vaccine development is the probability of allergenicity since many vaccines stimulate the immune system into an allergic reaction. AllerTOP server was used to predict potential allergenicity and all of the epitopes were observed as ‘non-allergen’. IEDB class I immunogenicity tool was utilized to find the immunogenicity score of the peptides. Toxinpred server identified all peptides as ‘non-toxin’ along with hydrophobicity, hydrophilicity,
hydrophilicity, charge, SVM score, and molecular weight of the predicted peptides. Finally, two LBL, five CTL, and two HTL epitopes were chosen based on their conservancy, interaction with the greatest number of HLA alleles, antigenicity, immunogenicity, non-allergenicity, non-toxicity, and capacity to induce cytokine production. Geographical differences impact the development of subunit vaccines because they influence the variety of HLA allele expression throughout the world [48, 49].

The global population coverage of the finalized T-cell epitopes (CTL and HTL) with their corresponding HLA alleles was observed to be 99.25%. Finally, to ensure an immune response, KK, AAY, and GPGPG linkers were inserted between the LBL, CTL, and HTL epitopes to create a stable and effective vaccine design. β-defensins, a TLR4 agonist, was employed as an adjuvant and coupled to the N-terminal of the vaccine design using an EAAAK linker to increase the immunological response.

The final developed vaccine is 172 amino acids long and has a molecular weight of 18,294.07 Da, which falls within the optimal molecular weight range for chimeric vaccines. The suggested vaccine’s pI value (9.38), instability index (18.85), GRAVY score (−0.472), and aliphatic index (73.90) reflect its basic, stable, hydrophilic, and thermostable characteristics, respectively. Furthermore, the vaccine’s antigenicity (1.1569) and

Fig. 11 In silico simulation of immune response using vaccine as antigen. A antigen and immunoglobulins, B B-cell population, C B-cell population per state, D helper T-cell population, E helper T-cell population per state, F cytotoxic T-cell population per state, G macrophage population per state, H dendritic cell population per state, and I production of cytokine and interleukins with Simpson index D of immune response.
non-allergenicity further demonstrated its efficacy as a vaccination. Because better solubility of the recombinant protein within the E. coli host leads to faster separation and purification, solubility is one of the most fundamental and critical factors in vaccine manufacture. When the vaccine protein was overexpressed in the E. coli host, it was discovered to be soluble. Short half-lives of epitopes are often a worry while constructing vaccines and the proposed chimeric vaccine successfully demonstrated an acceptable stability index, indicating its potential as a vaccine candidate.

The secondary structure of the intended protein was expected to have 15.11 % helix, 27.32 % strands, and 57.55 % random coils after conformational analysis. Ramachandra plot showed that final vaccine protein have 81.4 % amino acid in the favorable section, 12.9 % amino acid in the additionally allowed zone, and 3.6 % amino acid in the prohibited region, indicating that the designed model is satisfactory. Furthermore, the ERRAT’s Z-score (92.661) and Verify3D showed that the structural quality of the vaccine construct was promising. As a consequence of the validation results, the tertiary structure appears to be suitable for future investigation.

Increasing protein stability is conferred the utmost importance in various biomedical and therapeutic applications. Disulfide engineering and a pair of mutations on the CYS11-CYS18 residue pair were used to improve the protein’s thermostability. The E.coli cell culture system is commonly utilized for bulk recombinant protein synthesis. As a result, codon optimization for E. coli strain K12 was carried out in order to achieve effective expression in the host. To ensure a higher degree of protein expression in E. coli, a GC content of 51.93 % was found, along with a codon adaptability index (CAI) of 1. Furthermore, the molecular docking experiment demonstrated that the proposed vaccine binds with low binding energy (856.6 kcal/mol) at the TLR4 receptor-binding site, demonstrating higher binding affinity. The stability and mobility of the TLR4-vaccine complex in the biological environment were assessed using a molecular dynamics simulation of the docked complex. The graph also showed that the protein–protein combination is extremely stable, with each residue exhibiting a decreased degree of deformation. Overall, molecular dynamics studies revealed that the suggested vaccine is sufficiently stable and has a low risk of deformability at the molecular level.

In addition, the immunological simulation results demonstrated that the vaccine design elicited an immune cascade against E. faecium that closely resembled the normal immune response to viral infections. Secondary and tertiary immune responses were shown to be stronger than primary immune responses after vaccination, with large amounts of antibodies produced and antigen cleared. The vaccination boosted both cell-mediated and humoral immunity, as seen by a rise in B-cells (memory B-cell and plasma B-cell) and T-cells (cytotoxic and helper T-cell). The vaccine design is capable of eliciting adequate antigen processing and presentation to CD4+ and CD8+ cells, as evidenced by the increased concentration of antigen processing cells such as dendritic cells and macrophages. However, further in vitro and in vivo experimental testing is needed to corroborate the in silico findings.

**Conclusion**

The present work offers a novel multi-epitope vaccine construct against E. faecium. Combination immunoinformatics, protein structure assessment, physicochemical and molecular dynamics studies confirmed the proposed vaccine to exhibit strong humoral and cellular immune response and holds a strong reasons for further experimental validation.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13099-022-00495-z.

Additional file 1: Table S1. Predicted B-cell epitopes epitopes from Enterococcus faecium penicillin binding protein and their corresponding MHC Class I alleles and their immunogenic properties. The final selected epitopes to design multi-epitope vaccine construct from proteins has been highlighted in green colour.

Additional file 2: Table S2. Predicted CTL epitopes from Enterococcus faecium penicillin binding protein with their corresponding MHC Class II alleles and their immunogenic properties. The final selected epitopes to design multi-epitope vaccine construct from proteins has been highlighted in green colour.

Additional file 3: Table S3. Predicted HTL epitopes from Enterococcus faecium penicillin binding protein with their corresponding MHC Class II alleles and their immunogenic properties. The final selected epitopes to design multi-epitope vaccine construct from proteins has been highlighted in green colour.

Additional file 4: Table S4. Population coverage analysis of the final vaccine construct using the population coverage analysis tool of the IEDB database by keeping the default parameters on (109 countries covering 16 different geographical regions).

Additional file 5: Table S5. Physicochemical properties, secondary structure, and solubility analysis of final vaccine construct as predicted by ProtParam tool, PSIPRED, and SOLpro server.

Additional file 6: Table S6. Disulfide engineering of the final multi-epitope vaccine.

Additional file 7: Table S7. Discontinuous B-cell epitopes with their scores predicted by ElliPro.

**Acknowledgements**

We would like to thank Mr. Krishn Kumar Verma (Associate—Scientific Visualizer, KIIT-TBI) for his contribution in designing graphical representation of figures. We acknowledge infrastructure support available through DBT-BUILDER program (BT/INF/22/SP42155/2021) at KIIT Deemed to Be University, Bhubaneswar.
Author contributions
Conception and design: JD, SRM, NM; computational work: JD, SRM, PJ, AT; data analysis and curation: TRK, TK, SP; writing—reviewing and editing: JD, SRM, NM. Supervision: NM, MS. The manuscript has been read and approved by all authors. Authors read and approved the final manuscript.

Funding
The present study is an inhouse exploratory research work, authors received no funding support from an external funding source.

Availability of data and materials
All data generated or analysed during this study are included in this published article (and its Additional files).

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interest.

Author details
1 School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to Be University, 751024, Bhubaneswar, India.
2 Department of Biotechnology & Bioinformatics, School of Life Sciences, JSS Academy of Higher Education & Research, Mysuru, India.
3 Biotechnology Industry Research Assistance Council (BIRAC), New Delhi, India.
4 Kalinga Institute of Medical Sciences, KIIT Deemed to Be University, Bhubaneswar, India.
5 KIIT-Technology Business Incubator (KIIT-TBI), Kalinga Institute of Industrial Technology (KIIT), Deemed to Be University, 751024, Bhubaneswar, India.

Received: 11 January 2022 Accepted: 26 April 2022
Published online: 27 May 2022

References

1. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology. 2009;155(6):1749–57.
2. Stewart S, Robertson C, Pan J, Kennedy S, Dancer S, Haahr L, et al. Epidemiology of healthcare-associated infection reported from a hospital-wide incidence study: considerations for infection prevention and control planning. J Hosp Infect. 2021;114:10–22.
3. Krawczyk B, Wityk P, Gałęcka M, Michalik M. The many faces of lactic acid bacteria. Microb Cell Fact. 2014;13(1):1–23.
4. Cassini A, Högborg LD, Phouchaux D, Quattrone A, Hoeha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
5. Ferede ZT, Tulull KD, Derese SG, Yeshanew AG. Prevalence and antimicrobial susceptibility pattern of Enterococcus species isolated from different clinical samples at black lion specialized teaching hospital, addis ababa. Ethiopia BMC Res Notes. 2018;11(1):1–6.
6. Billington EO, Phang SH, Gregson DB, Pitout JDD, Ross T, Church DL, Parkins MD. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis. 2014;26:76–82.
7. Barros CH, Falaz S, Stanisic D, Tasic L. Biogenic nanosilver against multidrug-resistant bacteria (MDRb). Antibiotics. 2018;7(3):69.
8. Chapot-Chartier MP, Kulakauskas S. Cell wall structure and function in lactic acid bacteria. Microb Cell Fact. 2014;13(1):1–23.
9. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol Rev. 2006;30(5):673–91.
10. Vermassen A, Lenry S, Talon R, Provot C, Popowska M, Desvaux M. Cell wall hydrolases in bacteria: insight on the diversity of cell wall amidases, glycosidases and peptidases toward peptidoglycan. Front Microbiol. 2019;10:331.
11. Popham DL, Young KD. Role of penicillin-binding proteins in bacterial cell morphogenesis. Curr Opin Microbiol. 2003;6(6):594–9.
12. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010;16(6):SS5–62.
13. Huebner J, Wang Y, Kuegler WA, Madoff LC, Martirossian G, Boisot S, Per G. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun. 1999;67(3):1213–9.
14. Romero-Saavedra F, Laverde D, Wobser D, Michaux C, Budin-Verneuil A, Bernay B, Huebner J. Identification of peptidoglycan-associated proteins as vaccine candidates for enterococcal infections. PLoS ONE. 2014;9(11):e111880.
15. Kodali S, Vinogradov E, Lin F, Khoury N, Hao L, Paviak V, Donald RG. A vaccine approach for the prevention of infections by multidrug-resistant Enterococcus faecium. J Biol Chem. 2015;290(32):19512–26.
16. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunology. 2010;133(4):530–41.
17. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–50.
18. Saha S, Raghava GPS. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006. https://doi.org/10.1002/prot.21078.
19. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS/MHC eluted ligand data. Nucleic Acids Res. 2020. https://doi.org/10.1093/nar/gkaa379.
20. Flint W, Paul S, Dhanda SK, Mahajan S, Xu X, Peters B, Sette A. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front Immunol. 2017;8:278.
21. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8(1):1–7.
22. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2—a server for in silico prediction of allergens. J Mol Model. 2014;20:1–6.
23. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GP. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE. 2013;8(8):e73957.
24. Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013;9(10):e1003266.
25. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006;7(1):1–5.
26. Li W, Yosh MD, Singhana S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines. 2014;2(3):515–36.
27. Dey et al. Gut Pathogens           (2022) 14:21
28. McGuffin LJ, Blyson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics. 2000;16:404–5.
29. Craig DG, Dombkowski AA. Disulﬁde by Design 2.0: a web-based tool for disulﬁde engineering in proteins. BMC Bioinformatics. 2013;14:1–7.
30. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, Peters G. ElliPredict: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008;9(1):1–8.
31. Morris GM, Huey R, Lindstorm W, Sanner MF, Belewu RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2015;36(23):2180–2202.
32. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701–18.
34. Asad Y, Ahmad S, Rungrotmongkol T, Ranaghan KE, Azam SS. Immuno-informatics driven proteome-wide investigation revealed novel peptide-based vaccine targets against emerging multiple drug resistant Providencia stuartii. J Mol Graph Model. 2018;80:238–50.

35. Mahapatra SR, Sahoo P, Patnaik S, Patro S, Misra N, Suar M. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection. Expert Rev Vaccines. 2020;19(9):871–85.

36. Baser S, Ahmad S, Ranaghan KE, Azam SS. Towards a peptide-based vaccine against Shigellasonnei: a subtractive reverse vaccinology based approach. Biologicals. 2017;50:87–99.

37. Dey J, Mahapatra SR, Lata S, Patro S, Misra N, Suar M. Exploring Klebsiella pneumoniae capsule polysaccharide proteins to design multiepitope subunit vaccine to fight against pneumonia. Expert Rev Vaccines. 2022;4:1–19.

38. Hossain MI, Chowdhury AS, Hossain MU, Khan MA, Mahmood TB, Misan S. Immunoinformatics aided-design of novel multi-epitope based peptide vaccine against Hendra henipavirus through proteome exploration. Inform Med Unlocked. 2021;25: 100678.

39. Mahapatra SR, Dey J, Kaur T, Sarangi R, Rajoria AA, Kushwaha GS, Suar M. Immunoinformatics and molecular docking studies reveal a novel multi-epitope peptide vaccine against pneumonia infection. Vaccine. 2021;39(43):6221–37.

40. Nezafat N, Karimi Z, Esfami M, Mohkam M, Zandian S, Ghasemi Y. Designing an efficient multi-epitope peptide vaccine against Vibrio cholerae via combined immunoinformatics and protein interaction based approaches. Comput Biol Chem. 2016;62:82–95.

41. Chatterjee R, Sahoo P, Mahapatra SR, Dey J, Ghosh M, Kushwaha GS, et al. Development of a conserved chimeric vaccine for induction of strong immune response against staphylococcus aureus using immunoinformatics approaches. Vaccines. 2021;9(9):1038.

42. Nain Z, Abdulla F, Rahman MM, Karim MM, Khan MSA, Sayed SB, et al. Proteome-wide screening for designing a multi-epitope vaccine against emerging pathogen Elizabethkingia anophelis using immunoinformatic approaches. J Biomol Struct Dyn. 2020;38(16):4850–67.

43. Mahapatra SR, Dey J, Kushwaha GS, Puhan P, Mohakud NK, Panda, et al. Immunoinformatic approach employing modeling and simulation to design a novel vaccine construct targeting MDR efflux pumps to confer wide protection against typhoidal Salmonella serovars. J Biomol Struct Dyn. 2021. https://doi.org/10.1080/07391102.2021.1964600.

44. Sayed SB, Nain Z, Khan MSA, Abdulla F, Tasmin R, Adhikari UK. Exploring lassa virus proteome to design a multi-epitope vaccine through immunoinformatics and immune simulation analyses. Int J Pept Res Ther. 2020;26(4):2089–107.

45. Rostamtabar M, Rahmani A, Aabae M, Karkhal A, Pranjapati VK, Ebrahimpouri S, Nouri HR. Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches. Infect Genet Evol. 2019;75: 103992.

46. Abdullah M, Kadivella M, Sharma R, Faisal SM, Azam S. Designing of multiepitope-based vaccine against Leptospirosis using immuno-informatics approaches. BioXiv. 2021. https://doi.org/10.1101/2021.02.22.431920.

47. Kalliaoudou E, Huebner J. Advances and prospects in vaccine development against Enterococci. Cells. 2020;9(11):2397.

48. Dey J, Mahapatra SR, Singh P, Patro S, Kushwaha GS, Misra N, Suar M. B and T cell epitope-based peptides predicted from clumping factor protein of Staphylococcus aureus as vaccine targets. Microb Pathog. 2021;160: 105171.

49. Dey J, Mahapatra SR, Patnaik S, Lata S, Kushwaha GS, Panda RK, et al. Molecular characterization and designing of a novel multiepitope vaccine construct against Pseudomonas aeruginosa. Int J Pept Res Ther. 2022;28(2):1–19.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.